为了解决这个问题,科学家们发明了一种叫做GLP-1受体激动剂(GLP-1 receptor agonist)的药物。这种药物能够模拟GLP-1的结构和功能,与人体内的GLP-1受体结合,从而发挥类似于GLP-1的作用。与GLP-1不同的是,GLP-1受体激动剂具有更长的半衰期,能够在人体内持续存在和发挥效果。因此,GLP-1受体激动剂能够有效地降低血糖...
In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory...
大会首日,上海交通大学医学院附属瑞金医院王继光教授分享了首个口服胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)的心血管结局研究——SOUL(Semaglutide cardiOvascular oUtcomes triaL),主要结果作为最新突破性...
This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists (GLP-1RAs) or other antihyperglycemics. GLP-1RAs reduce risks of neurocognitive, substance use, cardiovascular and respiratory disorders, but increase risks of gastrointestinal ...
GLP-1及其类似物 胰高血糖素样肽(Glucagon-Like Peptide,GLP-1)是由肠道分泌的一种内源性肽类激素,促进胰岛素分泌并抑制胰高血糖素的分泌。胰高血糖素样肽-1受体激动剂(Glucagon-Like Peptide-1 Receptor Agonist,GLP-1RA )是GLP-1经结构修饰所得的GLP-1类似物,提高体内活性GLP-1水平,降低血糖。 上游制备工...
Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In placebo-controlled trials, cholelithiasis was reported in 1% of patients treated with RYBELSUS® 7 mg. Cholelithiasis was no...
Mounjaro(tirzepatide) is aonce-weekly injectionthat’s closely related to GLP-1 receptor agonist drugs. It’s part of a brand new class called GLP-1/GIP agonists. Itworks bymimicking two gut hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). ...
GLP-1 Receptor Agonist drug class usage statistics for the United States (2013 - 2022). Statistics include a comparison of all drugs within the drug class of GLP-1 Receptor Agonist.
文章导读：司美格鲁肽（Semaglutide, 最初译为索马鲁肽）由糖尿病制药巨头诺和诺德开发，是一种新型的长效胰高糖素样肽‑1受体激动剂（GLP‑1RA , glucagon‑like peptide‑1 receptor agonist），也称胰高糖素样肽‑1类似物（GLP-1类似物）。2017年12月，司美格鲁肽首次在美国FDA获批上市，2018年2月于...
Drugs like Ozempic, Wegovy and Mounjaro have been around for years, but they've recently been making headlines due to a rise in popularity as weight loss agents. They all belong to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), which mimic a hormone (GL...